Version 1
: Received: 17 August 2023 / Approved: 18 August 2023 / Online: 18 August 2023 (11:36:31 CEST)
Version 2
: Received: 21 August 2023 / Approved: 22 August 2023 / Online: 23 August 2023 (07:49:13 CEST)
How to cite:
Rus, M.; Crisan, S.; Andronie-Cioara, F. L.; Indries, M.; Marian, P.; Pobirci, L. O.; Ardelean, A. I. Management and Risk Factors of Atrial Fibrillation. Preprints2023, 2023081359. https://doi.org/10.20944/preprints202308.1359.v2
Rus, M.; Crisan, S.; Andronie-Cioara, F. L.; Indries, M.; Marian, P.; Pobirci, L. O.; Ardelean, A. I. Management and Risk Factors of Atrial Fibrillation. Preprints 2023, 2023081359. https://doi.org/10.20944/preprints202308.1359.v2
Rus, M.; Crisan, S.; Andronie-Cioara, F. L.; Indries, M.; Marian, P.; Pobirci, L. O.; Ardelean, A. I. Management and Risk Factors of Atrial Fibrillation. Preprints2023, 2023081359. https://doi.org/10.20944/preprints202308.1359.v2
APA Style
Rus, M., Crisan, S., Andronie-Cioara, F. L., Indries, M., Marian, P., Pobirci, L. O., & Ardelean, A. I. (2023). Management and Risk Factors of Atrial Fibrillation. Preprints. https://doi.org/10.20944/preprints202308.1359.v2
Chicago/Turabian Style
Rus, M., Lilliana Oana Pobirci and Adriana Ioana Ardelean. 2023 "Management and Risk Factors of Atrial Fibrillation" Preprints. https://doi.org/10.20944/preprints202308.1359.v2
Abstract
Atrial fibrillation (AF) is a common arrhythmia associated with various risk factors and significant morbidity and mortality. This article presents findings from a study involving 115 patients with permanent AF. The study examined demographics, risk factors, associated pathologies, complications, and anticoagulant therapy. The results showed a slight predominance of AF in males, with the highest incidence in individuals aged 75 and above. Common risk factors included arterial hypertension, dyslipidaemia, diabetes mellitus type 2, and obesity. Comorbidities such as congestive heart failure, mitral valve regurgitation, and pulmonary disorders were prevalent among the patients. Major complications included congestive heart failure, stroke, and myocardial infarction. Thromboembolic and bleeding risk assessment using CHAD2DS2-VASc and HAS-BLED scores demonstrated a high thromboembolic risk in all patients. The majority of patients were receiving novel oral anticoagulants (NOACs) before admission, while NOACs were also the most prescribed antithrombotic therapy at discharge. The study highlights the importance of risk factor management and appropriate anticoagulant therapy in AF patients to reduce complications and improve outcomes.
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.